This page summarises figures released under Freedom of Information legislation in 2019 about approvals for medicinal cannabis products in Australia. The data covered the period from November 2017 to November 2018 and showed a gradual increase in approvals over that time.
Three data sets were described: approvals per month by state and territory, approvals by condition or symptom, and approvals by type of product.
The distribution of approvals between jurisdictions was uneven.
The listed reasons for approvals included epilepsy, anorexia, muscle spasticity and psychological disorders, with pain and cancer-related symptoms accounting for the largest share. Products containing only CBD outnumbered those containing THC by more than four to one.
Published material notes that in the Poison Standard CBD was a prescription-only substance and THC a Schedule 8 controlled substance, the same schedule that includes opioids. The figures are approval counts and do not by themselves measure the number of patients.
For wider context see the policy page. The Therapeutic Goods Administration and the Office of Drug Control are the official sources on these matters. This is general information only; a licensed health professional is the right source of personal health advice.
© Steadfast Patient Notes | Privacy and cookies | Email: contact@unitedincompassion.com.au